We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.54B
AUM Growth
+$917M
Cap. Flow
+$287M
Cap. Flow %
8.11%
Top 10 Hldgs %
51.42%
Holding
131
New
31
Increased
26
Reduced
8
Closed
26

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$88M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$70.6M
3
BPMC
Blueprint Medicines
BPMC
+$30.6M
4
AMRN
Amarin Corp
AMRN
+$30M
5
TDOC icon
Teladoc Health
TDOC
+$26.6M

Top Sells

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$105M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$71M
3
ARGX icon
argenx
ARGX
+$53.9M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$41M
5
XLRN
Acceleron Pharma
XLRN
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.47%
2 Financials 0.51%
3 Technology 0.04%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$18.3B
$331M 9.34%
3,758,662
-849,892
-18% -$71M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$294M 8.3%
21,639,486
+915,062
+4% +$11.2M
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
$292M 8.25%
5,525,726
+100,000
+2% +$4.91M
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$213M 6.01%
3,869,491
+79,275
+2% +$3.77M
AMRN
5
Amarin Corp
AMRN
$298M
$136M 3.83%
327,048
+83,268
+34% +$30M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.8B
$131M 3.7%
1,113,328
+60,681
+6% +$5.31M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$2.04B
$116M 3.28%
12,235,811
-5,300
-0% -$51.5K
MGTX icon
8
MeiraGTx Holdings
MGTX
$1.08B
$104M 2.92%
6,007,746
+1,304,348
+28% +$18.4M
ARRY
9
DELISTED
Array Biopharma Inc
ARRY
$103M 2.91%
+4,228,900
New +$88M
BPMC
10
DELISTED
Blueprint Medicines
BPMC
$102M 2.87%
1,271,054
+413,728
+48% +$30.6M
QTNT
11
DELISTED
Quotient Limited Ordinary Shares
QTNT
$97.2M 2.74%
269,726
– –
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$85.3M 2.41%
1,164,382
+1,038,507
+825% +$70.6M
TVTX icon
13
Travere Therapeutics
TVTX
$5.14B
$69.1M 1.95%
3,054,707
-287,331
-9% -$6.35M
RGNX icon
14
Regenxbio
RGNX
$617M
$65.7M 1.85%
1,145,726
+500,000
+77% +$24.8M
MMSI icon
15
Merit Medical Systems
MMSI
$4.74B
$65.1M 1.84%
1,053,098
+103,900
+11% +$5.89M
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
$62.8M 1.77%
1,400,171
-30,000
-2% -$1.38M
ATNX
17
DELISTED
Athenex, Inc. Common Stock
ATNX
$62.4M 1.76%
254,801
– –
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$8.88B
$58.9M 1.66%
2,587,953
– –
CBAY
19
DELISTED
Cymabay Therapeutics
CBAY
$55.9M 1.58%
4,212,821
+1,750,000
+71% +$18.6M
ALBO
20
DELISTED
Albireo Pharma Inc
ALBO
$54.9M 1.55%
1,704,330
– –
MYOK
21
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$51.4M 1.45%
988,511
-86,705
-8% -$3.99M
NVTA
22
DELISTED
Invitae Corporation
NVTA
$50.9M 1.44%
2,171,918
+308,512
+17% +$5.44M
ALLO icon
23
Allogene Therapeutics
ALLO
$583M
$44.6M 1.26%
1,543,790
– –
VBIV
24
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$42.6M 1.2%
798,385
– –
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$41.8M 1.18%
2,875,000
+50,000
+2% +$639K
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Perceptive Advisors held 131 positions worth $3.54B, up 35% from $2.63B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors deployed $287M of net new capital in Q1 2019, opening 31 new positions and adding to 26 existing holdings. Its largest new stake was Array Biopharma Inc: 4,228,900 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $71M trimmed.

  • Perceptive Advisors's largest Q1 2019 buy was Array Biopharma Inc: 4,228,900 shares worth $103M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q1 2019, an estimated $70.6M increase.
  • Perceptive Advisors's biggest Q1 2019 reduction was Neurocrine Biosciences, cutting an estimated $71M.
  • Perceptive Advisors fully exited Solid Biosciences in Q1 2019, selling an estimated $105M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $3.54B portfolio in Q1 2019.
  • Perceptive Advisors opened 31 new positions and closed 26 in Q1 2019.
  • Perceptive Advisors's portfolio value rose 35% quarter-over-quarter to $3.54B.

Based on Perceptive Advisors's 13F filing for Q1 2019, filed 15 May 2019.